Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B
This article was originally published in The Pink Sheet Daily
Executive Summary
News on melanoma could put the biotech’s lucrative partnership with GlaxoSmithKline in jeopardy.
You may also be interested in...
How A Biomarker Revived Synta’s Cancer Drug Elesclomol
Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.
How A Biomarker Revived Synta’s Cancer Drug Elesclomol
Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.
Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data
ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.